Exyn Technologies (EXYN) Registration filing summary

Use of proceeds and capital allocation

• Net proceeds from the IPO will be used for growth capital, working capital, and repayment of certain indebtedness, including $3.5M under the Western Alliance Bank loan, $1.5M under the Neolync Convertible Note, $0.6M under the Maximcash Loan, $0.75M under the NCH Convertible Note, and $1.5M under the Neolync Term Loan.

• Any remaining proceeds will be used for general corporate purposes.

• The company will not pay dividends for the foreseeable future; future dividend policy will depend on earnings, capital requirements, and other factors.

Offering details and pricing

• The IPO consists of units, each containing one share of common stock and one warrant to purchase one share of common stock.

• Warrants are exercisable immediately at 125% of the IPO price and expire five years from issuance.

• The company has applied to list its common stock and warrants on Nasdaq under the symbols “EXYN” and “EXYNW.”

• Underwriters have a 30-day option to purchase additional shares and/or warrants.

• The offering is led by Lucid Capital Markets, LLC.

Underwriters and syndicate

• Lucid Capital Markets, LLC is the lead underwriter and representative.

• Underwriters receive a 2.5% warrant coverage and have a right of first refusal for future investment banking services for 12 months post-IPO.

• Underwriters are indemnified by the company for certain liabilities, including under the Securities Act.